se ha leído el artículo
array:19 [ "pii" => "X0211699504029786" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2050 "formatos" => array:3 [ "EPUB" => 221 "HTML" => 1380 "PDF" => 449 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699504029778" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:11-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2581 "formatos" => array:3 [ "EPUB" => 227 "HTML" => 1872 "PDF" => 482 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Efecto del losartan sobre la muerte cardíaca súbita en personas con diabetes: estudio LIFE" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "11" "paginaFinal" => "12" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. LINDHOLM" "autores" => array:1 [ 0 => array:1 [ "nombre" => "L. LINDHOLM" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029778?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029778/v0_201502091335/en/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699504029794" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:8-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3584 "formatos" => array:3 [ "EPUB" => 259 "HTML" => 2623 "PDF" => 702 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Óxido nítrico y remodelación vascular: papel de las metalopreatasas de matriz extracelular" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "8" "paginaFinal" => "9" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. LAMAS , C. ZARAGOZA" "autores" => array:1 [ 0 => array:1 [ "nombre" => "S. LAMAS , C. ZARAGOZA" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029794?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029794/v0_201502091335/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "10" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. DE ZEEUW" "autores" => array:1 [ 0 => array:1 [ "nombre" => "D. DE ZEEUW" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión D. de Zeeuw University Medical Center. Groningen. The Netherlands. Patients with renal disease not only run a great risk of end-stage-renal failure, but also high risk for cardiovascular morbidity and mortality. Indeed, a decreased glomerular filtration rate or a excessive leak of proteins in the urine are prime risk markers for CV morbidity and mortality. As far as protein leaks are concerned, even low range leakage called microalbuminuria (30-300 mg/day) appears to be such a marker. The classical cardiovascular risk profiling is based on glucose metabolism (diabetes), blood pressure, cholesterol, smoking (overweight, and lifestyle). These parameters not only allow us to classify the risk of a patient in the office, but they also allowed us to justify our therapeutic strategies. These therapies are aimed at reducing these risk factors/markers. Indeed, metabolic control of glucose was a big step in preventing the life threatening end-organ effects of type 2 diabetes. Even more impressive effects were seen when one controls blood pressure on end-organ damage. Recently, lowering of cholesterol has been added to this cardiovascular protective armamentarium. By far the biggest additive step has been made recently by the introduction of tools to intervene in the renin-angiotensin-aldosteron system, such as ACE-inhibitors and AII-antagonists. These drugs add to cardiovascular protection beyond blood pressure and blood glucose control (HOPE, LIFE, CHARM). Interestingly, renal function as well as urinary protein excretion independently contribute to the above classical risk factors for CV morbidity and mortality. In fact, serum creatinine (GFR) and proteinuria are in many studies both in the general population, as well as in other risk groups such as hypertensives, the strongest predictors of CV risk. Recent data have shown that if one targets the kidney with renoprotective antihypertensive therapies such as ACE-inhibitors and AIIA antagonist (IRMA2, IDNT, RENAAL), one may also protect the heart. In fact, unpublished data show that the more one protects the kidney the more one protects the heart. Thus, not only are patients with a compromised renal function (either low GFR or high proteinuria or both) at markedly higher CV risk, they also are responding as good or even better to CV protective therapy. These data urge us to address the question: should we not target and titrate our therapy to improving the kidney to obtain a maximal effect on CV risk. This question is not only relevant in secondary prevention, but certainly also in primary prevention. Data will be presented to make that case. This opens the door for multi-organ disease management and therapy in an ever growing disease 10 " "pdfFichero" => "P7-E232-S132-A2967.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/main.assets" "Apartado" => array:4 [ "identificador" => "35393" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Artículos Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/P7-E232-S132-A2967.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029786?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 7 | 6 | 13 |
2024 Octubre | 30 | 32 | 62 |
2024 Septiembre | 35 | 28 | 63 |
2024 Agosto | 32 | 61 | 93 |
2024 Julio | 37 | 32 | 69 |
2024 Junio | 57 | 32 | 89 |
2024 Mayo | 41 | 33 | 74 |
2024 Abril | 43 | 34 | 77 |
2024 Marzo | 25 | 15 | 40 |
2024 Febrero | 26 | 36 | 62 |
2024 Enero | 34 | 23 | 57 |
2023 Diciembre | 25 | 32 | 57 |
2023 Noviembre | 34 | 30 | 64 |
2023 Octubre | 30 | 43 | 73 |
2023 Septiembre | 20 | 29 | 49 |
2023 Agosto | 32 | 22 | 54 |
2023 Julio | 29 | 31 | 60 |
2023 Junio | 25 | 27 | 52 |
2023 Mayo | 48 | 26 | 74 |
2023 Abril | 20 | 24 | 44 |
2023 Marzo | 23 | 16 | 39 |
2023 Febrero | 24 | 30 | 54 |
2023 Enero | 24 | 24 | 48 |
2022 Diciembre | 36 | 39 | 75 |
2022 Noviembre | 31 | 34 | 65 |
2022 Octubre | 27 | 50 | 77 |
2022 Septiembre | 33 | 26 | 59 |
2022 Agosto | 36 | 42 | 78 |
2022 Julio | 29 | 45 | 74 |
2022 Junio | 22 | 32 | 54 |
2022 Mayo | 30 | 37 | 67 |
2022 Abril | 28 | 36 | 64 |
2022 Marzo | 35 | 41 | 76 |
2022 Febrero | 21 | 35 | 56 |
2022 Enero | 23 | 40 | 63 |
2021 Diciembre | 35 | 45 | 80 |
2021 Noviembre | 24 | 40 | 64 |
2021 Octubre | 17 | 33 | 50 |
2021 Septiembre | 25 | 45 | 70 |
2021 Agosto | 21 | 34 | 55 |
2021 Julio | 24 | 26 | 50 |
2021 Junio | 9 | 25 | 34 |
2021 Mayo | 24 | 29 | 53 |
2021 Abril | 23 | 56 | 79 |
2021 Marzo | 23 | 23 | 46 |
2021 Febrero | 17 | 17 | 34 |
2021 Enero | 30 | 21 | 51 |
2020 Diciembre | 11 | 15 | 26 |
2020 Noviembre | 22 | 8 | 30 |
2020 Octubre | 17 | 13 | 30 |
2020 Septiembre | 9 | 12 | 21 |
2020 Agosto | 28 | 9 | 37 |
2020 Julio | 13 | 16 | 29 |
2020 Junio | 9 | 17 | 26 |
2020 Mayo | 25 | 24 | 49 |
2020 Abril | 18 | 15 | 33 |
2020 Marzo | 19 | 14 | 33 |
2020 Febrero | 22 | 14 | 36 |
2020 Enero | 27 | 17 | 44 |
2019 Diciembre | 27 | 24 | 51 |
2019 Noviembre | 22 | 15 | 37 |
2019 Octubre | 10 | 9 | 19 |
2019 Septiembre | 14 | 13 | 27 |
2019 Agosto | 6 | 14 | 20 |
2019 Julio | 12 | 29 | 41 |
2019 Junio | 15 | 11 | 26 |
2019 Mayo | 15 | 27 | 42 |
2019 Abril | 37 | 35 | 72 |
2019 Marzo | 12 | 22 | 34 |
2019 Febrero | 7 | 11 | 18 |
2019 Enero | 16 | 14 | 30 |
2018 Diciembre | 29 | 24 | 53 |
2018 Noviembre | 37 | 13 | 50 |
2018 Octubre | 48 | 11 | 59 |
2018 Septiembre | 24 | 12 | 36 |
2018 Agosto | 21 | 9 | 30 |
2018 Julio | 21 | 8 | 29 |
2018 Junio | 15 | 9 | 24 |
2018 Mayo | 28 | 13 | 41 |
2018 Abril | 16 | 8 | 24 |
2018 Marzo | 15 | 9 | 24 |
2018 Febrero | 27 | 2 | 29 |
2018 Enero | 11 | 6 | 17 |
2017 Diciembre | 22 | 4 | 26 |
2017 Noviembre | 12 | 7 | 19 |
2017 Octubre | 18 | 4 | 22 |
2017 Septiembre | 13 | 7 | 20 |
2017 Agosto | 11 | 4 | 15 |
2017 Julio | 10 | 4 | 14 |
2017 Junio | 8 | 5 | 13 |
2017 Mayo | 14 | 4 | 18 |
2017 Abril | 19 | 5 | 24 |
2017 Marzo | 10 | 8 | 18 |
2017 Febrero | 18 | 5 | 23 |
2017 Enero | 6 | 3 | 9 |
2016 Diciembre | 7 | 4 | 11 |
2016 Noviembre | 13 | 5 | 18 |
2016 Octubre | 17 | 2 | 19 |
2016 Septiembre | 25 | 3 | 28 |
2016 Agosto | 66 | 1 | 67 |
2016 Julio | 85 | 3 | 88 |
2016 Junio | 48 | 0 | 48 |
2016 Mayo | 58 | 0 | 58 |
2016 Abril | 26 | 0 | 26 |
2016 Marzo | 28 | 0 | 28 |
2016 Febrero | 36 | 0 | 36 |
2016 Enero | 33 | 0 | 33 |
2015 Diciembre | 55 | 0 | 55 |
2015 Noviembre | 44 | 0 | 44 |
2015 Octubre | 23 | 0 | 23 |
2015 Septiembre | 38 | 0 | 38 |
2015 Agosto | 43 | 0 | 43 |
2015 Julio | 20 | 0 | 20 |
2015 Junio | 16 | 0 | 16 |
2015 Mayo | 11 | 0 | 11 |
2015 Abril | 6 | 0 | 6 |